Asia
BeiGene is starting off the week with a bang. Late Sunday the company announced positive preliminary topline results from its Phase II trial of tislelizumab, the company’s investigational checkpoint inhibitor for relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL).
Last year, Novartis’ multiple sclerosis drug Gilenya generated more than $3 billion in revenue, with a little more than half of that coming from sales in the United States. As the drug faces patent loss in the future, Novartis is fighting to preserve that revenue driver with multiple lawsuits.
The Chinese biopharma market is booming as more and more companies eye breaking into that rich market. Christophe Weber, chief executive officer of pharma giant Takeda, views its China programs as its second-biggest business behind the United States.
Fresh off its first Pipeline Day last week, Vivek Ramaswamy’s Roivant Sciences is taking aim at breaking into the Chinese market. Roivant has launched another company called Sinovant Sciences.
One month after sharing promising interim-Phase I data at the American Society of Clinical Oncology, China-based Ascentage Pharma secured $150 million in Series C financing that will be used to support the development of its pipeline.
A*STAR’s Institute of Molecular & Cell Biology (IMCB) in Singapore, along with the Mayo Clinic, identified a key epigenetic protein called H3.3 that helps convert skin cells into other types of cells via cellular reprogramming.
Otsuka Pharmaceutical, based in Tokyo, Japan, is acquiring Waltham, Massachusetts-based Visterra for $430 million in cash. The deal is expected to close in the third quarter of this year.
More and more pharma companies follow the trend of planning initial public offerings on the Hong Kong Stock Exchange. Another trend following this path is the number of prominent investment bankers who have left their firms for biotech companies in the former British colony.
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
PRESS RELEASES